|
|
|
 |
|
| FDA Advisory Committe Recommmends FDA Approval of Tamoxifen as a Breast Cancer Preventive |
|
|
1998/09/02 -The Food and Drug Administration's (FDA) Oncology Drugs Advisory Committee recommended on September 2, 1998 that the FDA approve the drug tamoxifen as a breast cancer preventive. The FDA is not bound by the committee's recommendations, but usually follows them. A final decision is expected in November.
Many questions remain to be answered about the long-term effectiveness of tamoxifen as a preventive. Women and their physicians need to make informed decisions about the risks and benefits of tamoxifen.
Joann Schellenbach
National Director Media Relations
American Cancer Society
212-382-2169
jschelle@cancer.org
|
|
|
|
|
